Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.52 USD | -2.95% | +12.15% | -3.93% |
Apr. 30 | Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target | MT |
Apr. 16 | Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
- Stock Market
- Equities
- DTIL Stock
- News Precision BioSciences, Inc.
- Precision BioSciences : Doses First Patient in Study Evaluating Combination Drug Therapy Against Multiple Myeloma